Report cover image

Ocular Pain - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 65 Pages
SKU # DEL18679881

Description

Ocular Pain - Pipeline Insight, 2024



DelveInsight’s, Ocular Pain - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Ocular Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Ocular Pain Understanding

Ocular Pain: Overview

Ocular neuropathic pain is a diagnosis of exclusion which refers to the heightened perception of pain in response to normally non-painful stimuli. It usually presents without any visible objective exam findings, making it extremely difficult to identify. For this reason, it is often misdiagnosed as dry eye disease. This activity describes the etiology, epidemiology, evaluation, treatment, and management of ocular neuropathic pain. Ocular neuropathic pain is an important differential to consider because many patients get misdiagnosed due to its significant overlap with dry eye disease. The disparity between signs and symptoms often results in patients being dismissed or considered malingering, hysterical, or psychosomatic.

""Ocular Pain - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Pain pipeline landscape is provided which includes the disease overview and Ocular Pain treatment guidelines. The assessment part of the report embraces, in depth Ocular Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Pain R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Pain.
This segment of the Ocular Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ocular Pain Drugs
  • APP13007: Formosa Pharmaceuticals
APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain after cataract surgery. APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration.
  • Ok-201: OKYO Pharma
OK-201, a lipidated cyclized bovine adrenal medulla (“BAM8”) analogue, a promising candidate for the treatment of neuropathic and inflammatory pain, was licensed from Tuffs University on February 21, 2018. OK-201 is designed to activate a human MAS-related G protein-coupled receptor, or MRGPR, which is a promising analgesic target. This receptor is expressed mainly in sensory neurons and is involved in the perception of pain. Activation of MRGPR by BAM8 peptides inhibits pain by modulating Ca2+ influx.

Further product details are provided in the report……..

Ocular Pain: Therapeutic Assessment

This segment of the report provides insights about the Ocular Pain drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Ocular Pain
There are approx. 12+ key companies which are developing the therapies for Ocular Pain. The companies which have their Ocular Pain drug candidates in the most advanced stage, i.e. Phase II include Formosa Pharmaceuticals.
  • Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Ocular Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Intranasal
  • Intrathecal
  • Intravenous
  • Oral
  • Oral/Intravenous
  • Parenteral
  • Subcutaneous
  • Subcutaneous/Intramuscular
  • Transdermal
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Antisense oligonucleotide
  • Gene therapy
  • Hormones
  • Neuropeptides
  • Oligonucleotides
  • Small Molecule
  • Triglyceride
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ocular Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Pain drugs.

Ocular Pain Report Insights
  • Ocular Pain Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Ocular Pain Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Ocular Pain drugs?
  • How many Ocular Pain drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Pain?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ocular Pain therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Ocular Pain and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Pharmaleads
  • Vyluma
  • Novaliq
  • Sun Pharma Advanced Research Company
  • Formosa Pharmaceuticals
  • On Target Therapeutics
  • Sylentis
  • Surface Ophthalmics
  • Reata Pharmaceuticals
  • Ocular Therapeutix
  • OKYO Pharma
Key Products
  • PL265
  • NVK032
  • EyeSol
  • SDN 037
  • APP13007
  • OK 101
  • Tivanisiran
  • Betamethasone ophthalmic
  • Omaveloxolone
  • PL 37
  • Bupivacaine ophthalmic insert
  • OK-201

Table of Contents

65 Pages
Introduction
Executive Summary
Ocular Pain: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ocular Pain– DelveInsight’s Analytical Perspective
Mid Stage Products (Phase III)
Comparative Analysis
SDN 037: Sun Pharma Advanced Research Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
APP13007: Formosa Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
OK-201: OKYO Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Ocular Pain Key Companies
Ocular Pain Key Products
Ocular Pain- Unmet Needs
Ocular Pain- Market Drivers and Barriers
Ocular Pain- Future Perspectives and Conclusion
Ocular Pain Analyst Views
Ocular Pain Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us